1 February 2024 in Radiology: Cardiothoracic Imaging
Purpose To compare left ventricular ejection fraction (LVEF) measured with echocardiography and cardiac MRI in individuals with cancer and suspected cardiotoxicity and assess the potential effect on downstream clinical decision-making. Materials and Methods In this prospective, single-center observational cohort study, participants underwent same-day two-dimensional (2D) echocardiography and cardiac MRI between 2011 and 2021. Participants with suboptimal image quality were excluded. A subset of 74 participants also underwent three-dimensional (3D) echocardiography. The agreement of LVEF derived from each modality was assessed using Bland-Altman analysis and at relevant thresholds for cardiotoxicity. Results A total of 745 participants (mean age, 60 years ± 5 [SD]; 460 [61.7%] female participants) underwent same-day echocardiography and cardiac MRI. According to Bland-Altman analysis, the mean bias was -3.7% ± 7.6 (95% limits of agreement [LOA]: -18.5% to 11.1%) for 2D echocardiography versus cardiac MRI. In 74 participants who underwent cardiac MRI, 3D echocardiography, and 2D echocardiography, the mean LVEFs were 60.0% ± 10.4, 58.4% ± 9.4, and 57.2% ± 8.9, respectively (P < .001). At the 50% LVEF threshold for detection of cardiotoxicity, there was disagreement for 9.3% of participants with 2D echocardiography and cardiac MRI. Agreement was better with 3D echocardiography and cardiac MRI (mean bias, -1.6% ± 6.3 [95% LOA: -13.9% to 10.7%]) compared with 2D echocardiography and cardiac MRI (mean bias, -2.8% ± 6.3 [95% LOA: -15.2% to 9.6%]; P = .016). Conclusion Two-dimensional echocardiography had variations of ±15% for LVEF measurement compared with cardiac MRI in participants with cancer and led to misclassification of approximately 10% of participants for cardiotoxicity detection. Three-dimensional echocardiography had better agreement with cardiac MRI and should be used as first-line imaging. Keywords: Echocardiography, MR Functional Imaging, Cardiac Supplemental material is available for this article. © RSNA, 2024.
22 November 2025 in La Presse Médicale
SRSivatharshini Ramalingam
4 October 2023 in The American Journal of Cardiology
ANAlexandre Nicole Nowbar
+4
There is growing interest in the role of coronary computed tomography angiography (CTA) in cardio-oncology. However, there is a paucity of real-world experience and outcome data for patients with cancer. This study sought to determine the clinical utility and prognostic value of coronary CTA in patients with cancer. In this prospective, single-center study, we recruited patients with cancer who underwent coronary CTA. Coronary artery disease (CAD) extent was classified as normal, nonobstructive (1% to 49% stenosis), and potentially obstructive (≥50% stenosis). Patients were followed up for a median of 9 months (interquartile range 3 to 30 months) for cancer-related deaths and major adverse cardiovascular events (MACEs) defined as nonfatal myocardial infarction, urgent unplanned revascularization, or cardiovascular death. The mean age of patients (n = 113) was 61 ± 12 years, and 68 were female (60%). The most common underlying cancers were breast (29%) and lymphoma (13%). A total of 25 patients had potentially obstructive CAD, most commonly of the left anterior descending artery. After coronary CTA, 88% statin-naive patients with potentially obstructive CAD were initiated on statin therapy. A total of 28/32 patients who were taking fluoropyrimidine chemotherapy (5-fluorouracil or capecitabine) continued therapy, of whom none had MACEs. Overall, there were no episodes of MACEs in this cohort and 11% had cancer-related deaths. Coronary CTA has an important role in the clinical decision-making in patients with cancer to detect CAD, initiate primary preventative therapy, and guide coronary revascularization. No MACEs occurred. Using this coronary CTA-guided approach, preventative therapy was initiated, and most patients continued prognostically important cancer therapy.
19 May 2026 in European Heart Journal
Dyslipidaemia in cancer patients presents several challenges with increasing survival of cancer patients. Dyslipidaemia and cancer treatments both increase atherosclerotic cardiovascular disease (ASCVD) risk; yet, most risk prediction scores for ASCVD do not include important cancer factors and thus underestimate true ASCVD. Some cancer therapies cause transient elevations of low-density lipoprotein cholesterol or triglycerides, or reduction in high-density lipoprotein cholesterol, occasionally to extreme levels requiring specific treatment and monitoring strategies. A range of lipid-lowering therapies can be used in cancer patients to manage cholesterol and triglycerides but of these, reliable data only exist for statins and ezetimibe for managing low-density lipoprotein cholesterol, and fibrates and Omega 3 fish oils for hypertriglyceridaemia. There are no robust randomized controlled trials conducted in cancer patients for reduction of adverse cardiovascular events and therefore current recommendations have been extrapolated from non-cancer trials. Cancer survivors may require combination therapies; yet, trials of newer lipid-lowering therapies excluded cancer patients and hence safety and efficacy data are limited. The initiation of lipid-lowering therapy in cancer patients requires an integration of several factors, which includes a careful assessment of ASCVD risk, drug–drug interactions, side-effect profiles, and prognosis. Further work is required to personalize individualized risk scores for ASCVD in cancer patients and survivors and new trials and ‘real-world’ or registry data would inform these existing data gaps. Beyond lipid management, the putative role of therapies such for statins as cardioprotective agent for anthracycline chemotherapy open novel avenues for further research as survival from many cancers continues to improve.
30 August 2026 in European Heart Journal
Background and Aims: Heart failure therapy (HFT) is routinely continued in breast cancer survivors after recovery from anti-HER2 cancer therapy-related cardiac dysfunction (CTRCD), despite limited evidence. HER-SAFE is the first randomized trial to assess HFT withdrawal in this population. Methods: In this open-label, multicentre, randomized controlled, non-inferiority trial, breast cancer survivors with recovered anti-HER2 CTRCD (asymptomatic, left ventricular ejection fraction [LVEF] ≥50%, normalized biomarkers) were randomized to HFT withdrawal or continuation. Antecedent CTRCD was mild (relative global longitudinal strain [GLS] decline >15%, LVEF ≥50%), moderate (LVEF fall >10% to <50%), or severe (LVEF <40%). The primary endpoint was a moderate or severe CTRCD event over 12 months analysed by intention to treat; secondary endpoints included serial cardiac function, biomarkers, and quality of life. Results: Between July 2023 and June 2025, 90 patients were randomized (all female; median age 50 years [IQR 43–59]; median 17.3 months [IQR 7.7–33.2] since CTRCD recovery; HFT predominantly renin–angiotensin system inhibitors [98%] and beta-blockers [88%])—46 randomized to HFT withdrawal (1 lost to follow-up) and 44 to continuation. The primary endpoint occurred in 1 of 45 with withdrawal (moderate asymptomatic CTRCD) vs 0 of 44 with continuation (between-group difference 2.2pp; 90% CI upper limit 9.4pp - below the pre-specified 10pp non-inferiority margin). No cardiovascular deaths, heart failure hospitalizations or symptomatic CTRCD occurred. Cardiac magnetic resonance imaging-derived LVEF remained stable in both arms at 12 months (between-group difference −0.8% [−2.0 to +0.4], P = .21). Conclusions: Among breast cancer survivors with recovered anti-HER2 CTRCD, HFT withdrawal was not associated with symptomatic events or significant between-group difference in LVEF at 12-months.
10 August 2026 in European Heart Journal - Digital Health
ARAlexandra Pons Rivarola
+8
Aims: Cancer therapy-related cardiac dysfunction (CTRCD) is a prevalent complication with adverse clinical implications. Guidelines have emphasized the need for reliable baseline risk prediction to guide prevention strategies. While machine learning (ML) has shown promise in cardiovascular medicine, the readiness of ML-based prognostic models for baseline CTRCD risk prediction in cardio-oncology remains unclear. Aims: To systematically review and critically appraise the performance, methodological quality, and clinical applicability of ML-based models for predicting baseline CTRCD risk. Methods and results: A search on Embase and Medline was conducted up to May 2026. Eligible studies used ML algorithms to estimate CTRCD risk prior to cancer treatment. Data were extracted using an adapted version of the CHARMS checklist. Risk of bias (ROB) and reporting quality were assessed using PROBAST and TRIPOD + AI. Nine studies were included. Seven studies included novel models using multiple clinical and imaging predictors, while two repurposed or validated existing AI-enhanced electrocardiography (ECG) models. The levels of discrimination were at least moderate (AUC 0.65–0.88), calibration was only reported in two studies, and external validation in one. Multiparametric models showed higher performance metrics than ECG-only models but were methodologically constrained. Overall, most studies were limited by variability in outcome definitions, low event rates, limited transparency in reporting, and a lack of reproducibility measures. Conclusion: Current ML-based models for predicting CTRCD remain underdeveloped for clinical use. The present findings highlight the need for further work to optimize models by incorporating rigorous study designs, with emphasis on methodological clarity, standardized outcome definitions, and external validation to improve reproducibility.